Compare SOS & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOS | RNAZ |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.0M |
| IPO Year | 2005 | 2021 |
| Metric | SOS | RNAZ |
|---|---|---|
| Price | $1.12 | $7.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 34.5K | 6.5K |
| Earning Date | 05-15-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $6.08 |
| 52 Week High | $8.92 | $20.99 |
| Indicator | SOS | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 27.01 |
| Support Level | $1.06 | $6.08 |
| Resistance Level | $1.56 | $9.37 |
| Average True Range (ATR) | 0.07 | 0.60 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 28.67 | 3.57 |
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.